188 related articles for article (PubMed ID: 34467453)
1. Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial.
Öcal O; Peynircioglu B; Loewe C; van Delden O; Vandecaveye V; Gebauer B; Zech CJ; Sengel C; Bargellini I; Iezzi R; Benito A; Schütte K; Gasbarrini A; Seidensticker R; Wildgruber M; Pech M; Malfertheiner P; Ricke J; Seidensticker M
Eur Radiol; 2022 Feb; 32(2):1320-1329. PubMed ID: 34467453
[TBL] [Abstract][Full Text] [Related]
2. Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial.
Öcal O; Rössler D; Gasbarrini A; Berg T; Klümpen HJ; Bargellini I; Peynircioglu B; van Delden O; Schulz C; Schütte K; Iezzi R; Pech M; Malfertheiner P; Sangro B; Ricke J; Seidensticker M
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2487-2496. PubMed ID: 34541612
[TBL] [Abstract][Full Text] [Related]
3. Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin-bilirubin grading system.
Takatsu Y; Kobayashi S; Miyati T; Shiozaki T
Eur J Radiol; 2016 Dec; 85(12):2206-2210. PubMed ID: 27842668
[TBL] [Abstract][Full Text] [Related]
4. Liver functional assessment using time-associated change in the liver-to-spleen signal intensity ratio on enhanced magnetic resonance imaging: a retrospective study.
Kudo M; Gotohda N; Sugimoto M; Kobayashi S; Konishi M; Kobayashi T
BMC Surg; 2023 Jun; 23(1):179. PubMed ID: 37370103
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance elastography as a predictor of insufficient liver enhancement on gadoxetic acid-enhanced hepatocyte-phase magnetic resonance imaging in patients with type C hepatitis and Child-Pugh class A disease.
Motosugi U; Ichikawa T; Muhi A; Sano K; Morisaka H; Ichikawa S; Araki T
Invest Radiol; 2012 Oct; 47(10):566-70. PubMed ID: 22955025
[TBL] [Abstract][Full Text] [Related]
6. Consistency of hepatocellular gadoxetic acid uptake in serial MRI examinations for evaluation of liver function.
Theilig D; Elkilany A; Schmelzle M; Müller T; Hamm B; Denecke T; Geisel D
Abdom Radiol (NY); 2019 Aug; 44(8):2759-2768. PubMed ID: 31025071
[TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests.
Kukuk GM; Schaefer SG; Fimmers R; Hadizadeh DR; Ezziddin S; Spengler U; Schild HH; Willinek WA
Eur Radiol; 2014 Oct; 24(10):2482-90. PubMed ID: 25030459
[TBL] [Abstract][Full Text] [Related]
8. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
Kim SS; Kim SH; Song KD; Choi SY; Heo NH
J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
[TBL] [Abstract][Full Text] [Related]
9. Prediction of post-hepatectomy liver failure using gadoxetic acid-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein invasion.
Tsujita Y; Sofue K; Komatsu S; Yamaguchi T; Ueshima E; Ueno Y; Kanda T; Okada T; Nogami M; Yamaguchi M; Tsurusaki M; Hori M; Fukumoto T; Murakami T
Eur J Radiol; 2020 Sep; 130():109189. PubMed ID: 32784077
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of liver function using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging based on a three-dimensional volumetric analysis system.
Kudo M; Gotohda N; Sugimoto M; Kobayashi T; Kojima M; Takahashi S; Konishi M; Hayashi R
Hepatol Int; 2018 Jul; 12(4):368-376. PubMed ID: 29860678
[TBL] [Abstract][Full Text] [Related]
11. Association between relative liver enhancement on gadoxetic acid enhanced magnetic resonance images and histologic grade of hepatocellular carcinoma.
Jin YJ; Cho SG; Lee KY; Kim JM; Lee JW
Medicine (Baltimore); 2017 Jul; 96(30):e7580. PubMed ID: 28746206
[TBL] [Abstract][Full Text] [Related]
12. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal hepatobiliary phase image in gadoxetic acid-enhanced liver MRI for the evaluation of the HCC: Predictive factors.
Ryeom H; Chang Y; Park SY; Cho SH; Yeo B; Je H; Baek J
Medicine (Baltimore); 2023 Nov; 102(46):e36176. PubMed ID: 37986292
[TBL] [Abstract][Full Text] [Related]
14. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.
Joo I; Kim SY; Kang TW; Kim YK; Park BJ; Lee YJ; Choi JI; Lee CH; Park HS; Lee K; Kim H; Yu E; Kang HJ; Ha SY; Kim JY; Ahn S; Jung ES; Kim BH; Han HS; Lee JM
Radiology; 2020 Aug; 296(2):335-345. PubMed ID: 32484414
[TBL] [Abstract][Full Text] [Related]
15. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
[TBL] [Abstract][Full Text] [Related]
16. Prediction of postoperative liver failure using gadoxetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma.
Jin YJ; Lee SH; Cho SG; Kim JH; Lee JW; Lee KY; Shin WY
J Gastroenterol Hepatol; 2016 Jul; 31(7):1349-56. PubMed ID: 26916616
[TBL] [Abstract][Full Text] [Related]
17. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases.
Beer L; Mandorfer M; Bastati N; Poetter-Lang S; Tamandl D; Stoyanova DP; Elmer MC; Semmler G; Simbrunner B; Hodge JC; Sirlin CB; Reiberger T; Ba-Ssalamah A
Eur Radiol; 2019 Dec; 29(12):6600-6610. PubMed ID: 31001679
[TBL] [Abstract][Full Text] [Related]
18. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
[TBL] [Abstract][Full Text] [Related]
19. Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only-A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort.
Seidensticker M; Steffen IG; Bargellini I; Berg T; Benito A; Gebauer B; Iezzi R; Loewe C; Karçaaltincaba M; Pech M; Sengel C; van Delden O; Vandecaveye V; Zech CJ; Ricke J
Curr Oncol; 2022 Jan; 29(2):565-577. PubMed ID: 35200551
[TBL] [Abstract][Full Text] [Related]
20. Relative enhancement index can be used to quantify liver function in cirrhotic patients that undergo gadoxetic acid-enhanced MRI.
Eiras-Araújo AL; Parente DB; da Silva AC; da Motta Rezende GF; Mendes GB; Luiz RR; de Oliveira Souza R; da Costa Generalis S; Rodrigues RS; Perez RM
Eur Radiol; 2023 Jul; 33(7):5142-5149. PubMed ID: 36651953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
